naptumomab estafenatox   Click here for help

GtoPdb Ligand ID: 9948

Synonyms: ABR-217620 | ABR217620 | Anyara (proposed trade name) | TTS CD3 | TTS-CD3
Immunopharmacology Ligand
Compound class: Antibody
Comment: Naptumomab estafenatox (ABR-217620) is an immuno-oncology clinical candidate biologic drug that is being developed by Active Biotech and NeoTX Therapeutics. It is a fusion protein containing a 5T4 (tumor-associated oncofetal trophoblast glycoprotein antigen) Fab moiety fused via the C terminus of the heavy chain to an engineered hybrid of Staphylococcus entertoxins A and E (SEA/E-120) superantigens [1]. Staphylococcal superantigens are secreted by the pathogen and stimulate a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines and potent T-cell-mediated killing of tumour cells. Naptumomab estafenatox targets the destructive power of SEA/E-120 to 5T4-expressing tumour cells. The SEA/E-120 moiety is engineered to reduce MHC class II binding affinity so as to reduce killing of bystander MHC class II positive cells.
Click here for help
Classification Click here for help
Compound class Antibody
Synonyms Click here for help
ABR-217620 | ABR217620 | Anyara (proposed trade name) | TTS CD3 | TTS-CD3
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 65
Other databases
ChEMBL Ligand CHEMBL1743045
GtoPdb PubChem SID 374883835